NEO Company Profile and Key Details

Q: Who are the executives of NEO?

Mr. Jeffrey S. Sherman M.B.A.Chief Financial OfficerMs. Cynthia J. DieterChief Accounting OfficerMr. Christopher Michael Smith BScChief Executive Officer & DirectorMr. Warren StonePres of Clinical DivisionMr. George A. CardozaPres & Chief Operating Officer of Lab OperationsMr. William Bishop BonelloChief Financial OfficerDr. Shashikant Kulkarni Facmg, M.B.A., M.S., Ph.D.Pres of Lab Operations & Chief Scientific OfficerMr. Hutan Hashemi J.D.Chief Compliance OfficerMs. Ali OlivioGen. Counsel & Corporation Sec.Mr. John MooneyChief Technology OfficerCharlie EidsonDirector of Investor Relations and Corporation Devel.Ms. Kathryn B. McKenzieChief Sustainability & Risk OfficerMr. Marcus B. Silva J.D., M.B.A.Senior Vice President & GM of Oncology DiagnosticsMr. Greg SparksChief Technology OfficerDr. Derek Lyle M.D.Chief Medical OfficerMr. Vishal SikriPres of Pharma Services, Pres of Advanced Diagnostics and Pres & CCO of InivataMs. Kendra SweeneyHead of Investor Relations & Capital MarketsMs. Alicia OlivoGen. Counsel & Corporation Sec.

NASDAQ : NEO

NeoGenomics

$11.35

-0.07-0.61%

At Close 4:00 PM

68.6

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

NeoGenomics, Inc. (NEO) stock declined over -0.61%, trading at $11.35 on NASDAQ, down from the previous close of $11.42. The stock opened at $11.29, fluctuating between $11.26 and $11.47 in the recent session.

Stock Snapshot

11.42

Prev. Close

293.71M

Market Cap

11.26

Day Low

-12.75

P/E Ratio

-0.89

EPS (TTM)

-0.24

Cash Flow per Share

11.29

Open

25.88M

Number of Shares

11.47

Day High

94.21%

Free Float in %

7.48

Book Value

1.2M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 09, 2026	11.38	11.47	11.20	11.35	1.2M
Feb 06, 2026	11.43	11.58	11.16	11.42	2.41M
Feb 05, 2026	11.97	12.08	11.24	11.27	1.5M
Feb 04, 2026	12.57	12.64	11.89	11.97	1.38M
Feb 03, 2026	12.39	12.68	12.17	12.50	1.22M
Feb 02, 2026	12.06	12.33	12.06	12.31	952.72K
Jan 30, 2026	12.26	12.41	11.81	12.06	1.29M
Jan 29, 2026	12.40	12.60	12.29	12.40	1.71M
Jan 28, 2026	12.58	12.59	12.21	12.38	1.14M
Jan 27, 2026	12.43	12.67	12.04	12.47	787.33K
Jan 26, 2026	12.75	13.08	12.38	12.43	973.41K
Jan 23, 2026	13.07	13.19	12.65	12.81	2.95M
Jan 22, 2026	12.63	13.29	12.58	12.97	1.45M
Jan 21, 2026	12.64	12.86	12.54	12.69	1.71M
Jan 20, 2026	12.40	12.66	12.28	12.64	1.47M
Jan 16, 2026	12.83	13.00	12.55	12.79	5.9M
Jan 15, 2026	13.19	13.29	12.80	12.83	1.95M
Jan 14, 2026	12.83	13.23	12.31	13.22	2.19M
Jan 13, 2026	12.55	13.25	12.49	12.93	2.55M
Jan 12, 2026	13.26	13.74	11.93	12.49	3.43M

Contact Details

Fort Myers, FL 33912

United States

https://www.neogenomics.com 239 768 0600

About Company

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Stock Peers

IDXX

-4.82-0.75%

IDEXX Laboratories, Inc.$639.79 MEDP

-11.69-2.16%

Medpace Holdings, Inc.$530.35 NTRA

7.54+3.71%

Natera, Inc.$210.58 ICLR

3.98+2.64%

ICON Public Limited Company$154.57 ILMN

-2.47-2.06%

Illumina, Inc.$117.25 GH

3.49+3.43%

Guardant Health, Inc.$105.34 EXAS

0.14+0.14%

Exact Sciences Corporation$103.32 GRAL

0.33+0.33%

GRAIL, Inc.$100.40 BLLN

1.8+1.99%

BillionToOne, Inc.$92.41 RDNT

-0.09-0.13%

RadNet, Inc.$69.15

Company Overview

NeoGenomics, Inc. (NASDAQ:NEO) closed at $11.35 USD, losing -$0.07 (-0.61%) from the previous close of $11.42. The stock is currently mid-range between its 52-week high and low $4.72 and $14.73. With a market capitalization of about $293.71 million, NeoGenomics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.58). Key stats such as the average daily volume over the past year has been around 1.83 million shares, volume is running light vs its 52-week average. Headquartered in Fort Myers, FL, NeoGenomics, Inc. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Anthony Zook, the company employs approximately 2,200 people and listed since March 16, 2004. NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 -8.44%, SMA50 -7.17%, SMA200 25.13%). The stock’s 14-day RSI is 37.31 (weak momentum), while the ATR of 0.54 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -22.95% below its high and over 140.47% above its low. Average 10-day trading volume of 1.42 million shares is below the 3-month average of 1.76 million, indicating normal recent market interest.

Valuation Metrics

NeoGenomics, Inc. trades at a P/E ratio of -2.56, slightly below the S&P 500 average, with a price-to-sales ratio of 0.41 and a price-to-book ratio of 0.35 suggesting the stock is closer to book value. The P/FCF stands at -17.23, also below market averages.

Dividend & Fair Value

NeoGenomics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$9.51. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 47.83% annually over the next five years. The latest quarter delivered EPS of -$1.06. The next quarter is forecast at $0.04. Next year's EPS is expected at $58.55. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 6 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $18.00 to $8.00. The high target offers 58.59% upside. The low target suggests -29.52% downside. The mean target is $12.59. This offers 10.93% upside. NeoGenomics, Inc. earnings surprise history is a mixed track record. The quarter that ended October 28, 2025, missed forecasts by -5402.05%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 849.37% in July 29, 2024.

Shareholding & Insider Activity

NeoGenomics, Inc. has 129.18 million shares outstanding. The public float is 119.99 million shares, elevated short interest at 5.36% of float. This equals 5.02 million shares. The short ratio is 2.08 days. Institutional investors hold 101.64% of the float. Insiders own 1.29%. VAN OORT DOUGLAS M holds 2.42 million shares, JONES STEVEN C has 1.00 million shares and Sherman Jeffrey Scott has 188.33 thousand shares. Over the past six months, insider transactions show net selling. They sold 43.04 thousand shares across 2 transactions.

Financial & Profitability Overview

Over the trailing twelve months, NeoGenomics generated $591.64M in revenue, or $4.71 per share. Gross margin was 41.34%, operating margin -18.21%, and net profit margin -14.87%. Returns are negative, with ROA at -5.23% and ROE at -9.34%.
On valuation metrics, NeoGenomics trades at a P/E of -2.56, P/S of 0.41 and P/B of 0.35. The current ratio is 3.91 and quick ratio is 3.62. Operationally, the company’s inventory turnover is 14.09 and cash conversion cycle is 85.51 days. Debt-to-equity is 0.49, supported by a cash flow-to-debt ratio of 0.03.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, NeoGenomics posted revenue of $591.64M, down slightly from $509.73M in the prior quarter. Gross profit was $244.60M (margin 41.34%). Operating income was - $107.74M (margin -18.2%). Net income was- $87.97M (EPS - $0.70).
The company ended the quarter with $415.20M in cash and short-term investments, a total debt of $611.68M, and net debt of $269.19M. Total assets were $1.68B, with equity of $941.54M. Financials further reflected weakness, with operating cash flow of - $1.95M, free cash flow of - $30.71M, and capital expenditures of - $28.75M.

Price Forecast & Outlook

Our AI price prediction model suggests that NeoGenomics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.32%, with price expected at $10.86 by February 20, 2026, within a range of $10.54 to $11.20 3-Month Outlook: Projected rise of 9.34%, reaching $12.41 by May 07, 2026, with a range of $11.50 to $13.20. 1-Year Outlook: Projected gain of 233.74%, with price at $37.88 by February 05, 2027, within a range of $31.10 to $50.45.

Key Takeaways

NeoGenomics, Inc. (NASDAQ:NEO) shares are flat 7.48% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows NeoGenomics, Inc. trading at a premium to the broader market with a P/E of -2.56. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $24.44, suggesting 115.33% upside. Our AI forecast model points to short-term weakness (-4.32% over two weeks), a medium-term rise (9.34% over three months), and a longer-term gain (233.74% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current NeoGenomics, Inc. (NEO) stock price?

NeoGenomics, Inc. (NASDAQ: NEO) stock price is $11.35 in the last trading session. During the trading session, NEO stock reached the peak price of $11.47 while $11.26 was the lowest point it dropped to. The percentage change in NEO stock occurred in the recent session was -0.61% while the dollar amount for the price change in NEO stock was - $0.07.

NEO's industry and sector of operation?

The NASDAQ listed NEO is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector. NeoGenomics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NEO?

Mr. Jeffrey S. Sherman M.B.A.
Chief Financial Officer
Ms. Cynthia J. Dieter
Chief Accounting Officer
Mr. Christopher Michael Smith BSc
Chief Executive Officer & Director
Mr. Warren Stone
Pres of Clinical Division
Mr. George A. Cardoza
Pres & Chief Operating Officer of Lab Operations
Mr. William Bishop Bonello
Chief Financial Officer
Dr. Shashikant Kulkarni Facmg, M.B.A., M.S., Ph.D.
Pres of Lab Operations & Chief Scientific Officer
Mr. Hutan Hashemi J.D.
Chief Compliance Officer
Ms. Ali Olivio
Gen. Counsel & Corporation Sec.
Mr. John Mooney
Chief Technology Officer
Charlie Eidson
Director of Investor Relations and Corporation Devel.
Ms. Kathryn B. McKenzie
Chief Sustainability & Risk Officer
Mr. Marcus B. Silva J.D., M.B.A.
Senior Vice President & GM of Oncology Diagnostics
Mr. Greg Sparks
Chief Technology Officer
Dr. Derek Lyle M.D.
Chief Medical Officer
Mr. Vishal Sikri
Pres of Pharma Services, Pres of Advanced Diagnostics and Pres & CCO of Inivata
Ms. Kendra Sweeney
Head of Investor Relations & Capital Markets
Ms. Alicia Olivo
Gen. Counsel & Corporation Sec.

How NEO did perform over past 52-week?

NEO's closing price is 140.47% higher than its 52-week low of $4.72 where as its distance from 52-week high of $14.73 is -22.95%.

How many employees does NEO have?

Number of NEO employees currently stands at 2,200.

Link for NEO official website?

Official Website of NEO is: https://www.neogenomics.com

How do I contact NEO?

NEO could be contacted at phone 239 768 0600 and can also be accessed through its website. NEO operates from 9490 NeoGenomics Way, Fort Myers, FL 33912, United States.

How many shares of NEO are traded daily?

NEO stock volume for the day was 1.2M shares. The average number of NEO shares traded daily for last 3 months was 1.83M.

What is the market cap of NEO currently?

The market value of NEO currently stands at $293.71M with its latest stock price at $11.35 and 25.88M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	2200
Beta	1.58
Sales or Revenue	$591.64M
5Y Sales Change%	0.56%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Diagnostics & Research

NEO Company Profile and Key Details

NeoGenomics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook

Valuation Metrics